Project Details
Projekt
The role of HRAS downstream signalling for the production of immunosuppressive metabolites in the microenvironment of HRAS-driven SCC (P13)
Subject Area
Dermatology
Hematology, Oncology
Hematology, Oncology
Term
since 2021
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 441891347
Activating HRAS mutations occur frequently in cutaneous squamous cell carcinomas (cSCCs). Their impact on immune modulation remains poorly defined. Using mouse models and human tumour material, we will address how HRAS activation in cSCCs mediates immune evasion. Our aims are: 1. to understand the immune modulatory actions of HRAS; 2. to evaluate combined targeting of HRAS, EGFR and immunosuppressive metabolites and 3. to investigate T cell exhaustion in high-risk cSCCs and its relation to HRAS mutations. Collectively, the combined knowledge obtained from these aims will be translated into improved and personalized treatment for high-risk cSCCs.
DFG Programme
Collaborative Research Centres
Subproject of
SFB 1479:
Oncogene-driven immune escape (OncoEscape)
Applicant Institution
Albert-Ludwigs-Universität Freiburg
